Research programme: small molecule therapeutics - Belharra Therapeutics/ Genentech
Alternative Names: small molecule therapeuticsLatest Information Update: 10 Feb 2023
At a glance
- Originator Belharra Therapeutics
- Developer Belharra Therapeutics; Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Immunological disorders; Neurodegenerative disorders
Most Recent Events
- 06 Jan 2023 Early research in Immunological disorders in USA (unspecified route) (Belharra Therapeutics website, January 2023)
- 06 Jan 2023 Early research in Neurodegenerative disorders in USA (unspecified route)
- 04 Jan 2023 Belharra Therapeutics and Genentech agree to co-develop small molecule therapeutics in the USA for Cancer, Autoimmune disorders and Neurogenerative disorders